Join

Compare · FLAG vs TECH

FLAG vs TECH

Side-by-side comparison of First Light Acquisition Group Inc. (FLAG) and Bio-Techne Corp (TECH): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both FLAG and TECH operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
  • TECH is the larger of the two at $14.42B, about 51.0x FLAG ($282.6M).
  • Over the past year, FLAG is up 0.0% and TECH is up 7.8% - TECH leads by 7.8 points.
  • TECH has hit the wire 6 times in the past 4 weeks while FLAG has been quiet.
  • TECH has more recent analyst coverage (22 ratings vs 0 for FLAG).
PerformanceFLAG+0.00%TECH-15.30%
2026-01-29+0.00%2026-04-24
MetricFLAGTECH
Company
First Light Acquisition Group Inc.
Bio-Techne Corp
Price
$27.42+268.55%
$54.19+3.79%
Market cap
$282.6M
$14.42B
1M return
+0.00%
+2.81%
1Y return
+0.00%
+7.82%
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Biological Products (No Diagnostic Substances)
Exchange
NYSE
NASDAQ
IPO
2021
News (4w)
0
6
Recent ratings
0
22
FLAG

First Light Acquisition Group Inc.

First Light Acquisition Group, Inc. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2021 and is headquartered in Reston, Virginia.

TECH

Bio-Techne Corp

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, and diagnostics and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment provides biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment provides diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and nucleic acid analysis products for use in diagnostic or research applications, as well as instruments and process control products for hematology, blood chemistry, blood gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Novus Biologicals, Tocris Biosciences, ProteinSimple, Advanced Cell Diagnostics, and ExosomeDx brands. Bio-Techne Corporation has a clinical research collaboration with Carterra Inc. for the study of COVID-19 variants. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.

Latest FLAG

Latest TECH